Printer Friendly

Lexicon Genetics extends gene targeting technology agreement.

Lexicon Genetics, Inc. (The Woodlands, TX) has extended its OmniBank Universal agreement with Boehringer Ingelheim Pharmaceuticals, Inc. Under the terms of the agreement, Boehringer Ingelheim will continue its access to Lexicon's OmniBank library through February 2004. Boehringer Ingelheim will also continue to have access to gene knockouts generated under Lexicon's patented gene targeting technologies with genetic alterations directed at specific drug targets of interest, and access to drug target validation data generated by Lexicon for specified targets. Financial terms of the arrangement were not disclosed.

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.

Lexicon Genetics, Inc.

COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Boehringer Ingelheim Pharmaceuticals Inc.; OmniBank Universal
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 1, 2003
Previous Article:Advanced Cell Technology revails in cloning patent dispute.
Next Article:Sangamo BioSciences granted zinc finger DNA-binding protein patent.

Related Articles
Lexicon Genetics sublicenses positive-negative selection and isogenic DNA technologies to Eli Lilly.
Valentis announces improved Geneswitch gene regulation system.
Valentis licenses technology to American Home for functional genomics research.
Lexicon discovers role of LG688 protein in inflammation.
Lexicon Genetics licenses patented gene targeting technology.
Lexicon Genetics grants license to AstraZeneca.
Lexicon Genetics, Bristol-Myers Squibb Establish Alliance.
Lexicon Genetics and Takeda establish collaboration to develop new drugs for high blood pressure.
MorphoSys and Boehringer Ingelheim start new antibody program.
Lexicon granted exclusive license to Cellectis' homologous recombination technology.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters